Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) Accumulated Depreciation & Amortization (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Accumulated Depreciation & Amortization for 15 consecutive years, with $91.4 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 34.97% to $91.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $91.4 million through Dec 2025, up 34.97% year-over-year, with the annual reading at $91.4 million for FY2025, 34.97% up from the prior year.
  • Accumulated Depreciation & Amortization hit $91.4 million in Q4 2025 for Ani Pharmaceuticals, up from $67.7 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $91.4 million in Q4 2025 to a low of $18.8 million in Q1 2021.
  • Historically, Accumulated Depreciation & Amortization has averaged $39.0 million across 5 years, with a median of $27.3 million in 2022.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 148.18% in 2022 and later grew 4.95% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $23.0 million in 2021, then soared by 148.18% to $57.0 million in 2022, then rose by 4.95% to $59.8 million in 2023, then increased by 13.28% to $67.7 million in 2024, then soared by 34.97% to $91.4 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for ANIP at $91.4 million in Q4 2025, $67.7 million in Q4 2024, and $59.8 million in Q4 2023.